NCT06952842View on ClinicalTrials.gov

Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 18, 2025

Primary Completion Date

June 18, 2030

Study Completion Date

June 18, 2045

Conditions
Retinitis Pigmentosa
Interventions
DRUG

ZVS203e

ZVS203e injection is a clear, transparent liquid containing a recombinant adeno-associated virus serotype 8 (rAAV8) vector that expresses humanized SauriCas9 protein and single guide RNA (sgRNA) targeting specific mutations in the RHO gene.

Trial Locations (1)

100191

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Chigenovo Co., Ltd

NETWORK

NCT06952842 - Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation | Biotech Hunter | Biotech Hunter